Janux Therapeutics, Inc.

JANX

US47103J1051

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-05 pm EDT			5-day change	1st Jan Change
39.9 ^USD	+3.64%		-4.75%	+271.85%

Jul. 01	Janux Therapeutics, Inc.(NasdaqGM:JANX) dropped from Russell Small Cap Comp Value Index	CI
Jul. 01	Janux Therapeutics, Inc.(NasdaqGM:JANX) dropped from Russell 3000 Value Index	CI

Janux Therapeutics, Inc.(NasdaqGM:JANX) dropped from Russell 2000 Value Index

July 30, 2024

Latest news about Janux Therapeutics, Inc.

Janux Therapeutics, Inc.(NasdaqGM:JANX) dropped from Russell Small Cap Comp Value Index	Jun. 30	CI
Janux Therapeutics, Inc.(NasdaqGM:JANX) dropped from Russell 3000 Value Index	Jun. 30	CI
Janux Therapeutics, Inc.(NasdaqGM:JANX) dropped from Russell 3000E Index	Jun. 30	CI
Janux Therapeutics, Inc.(NasdaqGM:JANX) dropped from Russell Microcap Index	Jun. 30	CI
Janux Therapeutics, Inc.(NasdaqGM:JANX) dropped from Russell 2500 Value Index	Jun. 30	CI
Janux Therapeutics, Inc.(NasdaqGM:JANX) dropped from Russell 2000 Value Index	Jun. 30	CI
Janux Therapeutics, Inc.(NasdaqGM:JANX) dropped from Russell Microcap Growth Index	Jun. 30	CI
Janux Therapeutics, Inc.(NasdaqGM:JANX) dropped from Russell 3000E Growth Index	Jun. 30	CI
Janux Therapeutics, Inc.(NasdaqGM:JANX) dropped from Russell Microcap Value Index	Jun. 30	CI
Janux Therapeutics, Inc.(NasdaqGM:JANX) dropped from Russell 3000E Value Index	Jun. 30	CI
Janux Therapeutics, Inc.(NasdaqGM:JANX) added to S&P Biotechnology Select Industry Index	Jun. 23	CI
Janux Therapeutics Insider Sold Shares Worth $45,043,975, According to a Recent SEC Filing	Jun. 06	MT
Janux Therapeutics Insider Sold Shares Worth $82,125,000, According to a Recent SEC Filing	Jun. 06	MT
Scotiabank Starts Janux Therapeutics With Sector Perform Rating	May. 30	MT
Certain Pre Funded Warrants of Janux Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2024.	May. 29	CI
Certain Stock Options of Janux Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2024.	May. 29	CI
Certain Common Stock of Janux Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 30-MAY-2024.	May. 29	CI
Wedbush Raises Janux Therapeutics' PT to $74 From $53, Keeps Outperform Rating	May. 08	MT
Janux Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
JonesTrading Starts Janux Therapeutics With Buy Rating, $70 Price Target	Apr. 16	MT
Sector Update: Health Care Stocks Slipping Late Afternoon	Apr. 10	MT
Sector Update: Health Care	Apr. 10	MT
Janux Therapeutics Said to be Considering Sale	Apr. 10	MT
Janux Therapeutics Considering Options, Including Sale, Bloomberg Reports	Apr. 10	MT
Janux Therapeutics Reportedly Weighs Possible Sale	Apr. 09	CI

Chart Janux Therapeutics, Inc.

Duration

Period

More charts

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidate includes JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr), being investigated in a Phase I clinical trial in adult subjects with metastatic castration-resistant prostate cancer (mCRPC). JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

Sector

Biotechnology & Medical Research

Calendar

2024-08-05 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Janux Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

39.9 USD

Average target price

63.12 USD

Spread / Average Target

+58.21%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
JANUX THERAPEUTICS, INC.	+271.85%	2B
MODERNA, INC.	+18.97%	44.44B
LONZA GROUP AG	+41.98%	40.03B
IQVIA HOLDINGS INC.	-10.06%	37.68B
ALNYLAM PHARMACEUTICALS, INC.	+31.15%	31.46B
CELLTRION, INC.	-7.79%	27.29B
ICON PUBLIC LIMITED COMPANY	+13.32%	26.29B
UNITED THERAPEUTICS CORPORATION	+43.05%	13.8B
MEDPACE HOLDINGS, INC.	+31.28%	12.46B
BIO-TECHNE CORPORATION	-7.41%	11.26B

Other Biotechnology & Medical Research